Search research articles
Contact Us
Filters
Showing results (191-200 of 210) with videos related to
Page
of 21
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 9, 2024
Long-Term Follow-Up of the Anthracyclines in Early Breast Cancer Trials (USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 [NRG Oncology])
Charles E Geyer, Joanne L Blum, Greg Yothers, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 27, 2017
Long-Term Follow-Up of Cardiac Function and Quality of Life for Patients in NSABP Protocol B-31/NRG Oncology: A Randomized Trial Comparing the Safety and Efficacy of Doxorubicin and Cyclophosphamide (AC) Followed by Paclitaxel With AC Followed by Paclitaxel and Trastuzumab in Patients With Node-Positive Breast Cancer With Tumors Overexpressing Human Epidermal Growth Factor Receptor 2
Patricia A Ganz, Edward H Romond, Reena S Cecchini, et al.
Annals of Surgical Oncology
|
November 20, 2016
The Effect on Surgical Complications of Bevacizumab Added to Neoadjuvant Chemotherapy for Breast Cancer: NRG Oncology/NSABP Protocol B-40
Harry D Bear, Gong Tang, Priya Rastogi, et al.
Journal of the National Cancer Institute
|
March 20, 2019
Stromal Tumor-infiltrating Lymphocytes in NRG Oncology/NSABP B-31 Adjuvant Trial for Early-Stage HER2-Positive Breast Cancer
Rim S Kim, Nan Song, Patrick G Gavin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 12, 2017
Anthracyclines in Early Breast Cancer: The ABC Trials-USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 (NRG Oncology)
Joanne L Blum, Patrick J Flynn, Greg Yothers, et al.
Ecancermedicalscience
|
June 17, 2014
Report on the international colloquium on cardio-oncology (rome, 12-14 march 2014)
Michael Ewer, Luca Gianni, Fabrizio Pane, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 23, 2023
<i>DPYD</i> Testing: Time to Put Patient Safety First
Sharyn D Baker, Susan E Bates, Gabriel A Brooks, et al.
Nature Communications
|
March 28, 2024
Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study
Filipa Lynce, Candace Mainor, Renee N Donahue, et al.
Nature Communications
|
May 10, 2024
Author Correction: Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study
Filipa Lynce, Candace Mainor, Renee N Donahue, et al.
Medrxiv : the Preprint Server for Health Sciences
|
December 18, 2023
Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study
Filipa Lynce, Candace Mainor, Renee N Donahue, et al.
Page
of 21
Search research articles
Search
Showing results (191-200 of 210) with videos related to
Sort By:
Page
of 21
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 9, 2024
Long-Term Follow-Up of the Anthracyclines in Early Breast Cancer Trials (USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 [NRG Oncology])
Charles E Geyer, Joanne L Blum, Greg Yothers, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 27, 2017
Long-Term Follow-Up of Cardiac Function and Quality of Life for Patients in NSABP Protocol B-31/NRG Oncology: A Randomized Trial Comparing the Safety and Efficacy of Doxorubicin and Cyclophosphamide (AC) Followed by Paclitaxel With AC Followed by Paclitaxel and Trastuzumab in Patients With Node-Positive Breast Cancer With Tumors Overexpressing Human Epidermal Growth Factor Receptor 2
Patricia A Ganz, Edward H Romond, Reena S Cecchini, et al.
Annals of Surgical Oncology
|
November 20, 2016
The Effect on Surgical Complications of Bevacizumab Added to Neoadjuvant Chemotherapy for Breast Cancer: NRG Oncology/NSABP Protocol B-40
Harry D Bear, Gong Tang, Priya Rastogi, et al.
Journal of the National Cancer Institute
|
March 20, 2019
Stromal Tumor-infiltrating Lymphocytes in NRG Oncology/NSABP B-31 Adjuvant Trial for Early-Stage HER2-Positive Breast Cancer
Rim S Kim, Nan Song, Patrick G Gavin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 12, 2017
Anthracyclines in Early Breast Cancer: The ABC Trials-USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 (NRG Oncology)
Joanne L Blum, Patrick J Flynn, Greg Yothers, et al.
Ecancermedicalscience
|
June 17, 2014
Report on the international colloquium on cardio-oncology (rome, 12-14 march 2014)
Michael Ewer, Luca Gianni, Fabrizio Pane, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 23, 2023
<i>DPYD</i> Testing: Time to Put Patient Safety First
Sharyn D Baker, Susan E Bates, Gabriel A Brooks, et al.
Nature Communications
|
March 28, 2024
Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study
Filipa Lynce, Candace Mainor, Renee N Donahue, et al.
Nature Communications
|
May 10, 2024
Author Correction: Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study
Filipa Lynce, Candace Mainor, Renee N Donahue, et al.
Medrxiv : the Preprint Server for Health Sciences
|
December 18, 2023
Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study
Filipa Lynce, Candace Mainor, Renee N Donahue, et al.
Page
of 21